acute coronary syndromes

Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI)

Lefradafiban(BIBU-104) is an oral platelet glycoprotein IIb/IIIa receptor antagonist for the study of angina pectoris and acute coronary syndromes.

Iodofiltic acid can be used in the adjuvant treatment of acute coronary syndromes (Zeus ACS) and can be imaged to detect myocardial ischemia.

Ticagrelor metabolite M5 (T437700) is a metabolite of Ticagrelor, the first reversible oral antagonist of P2Y12 receptor. Compared to Clopidogrel, Ticagrelor has faster and more consistent inhibition on ADP-receptors. Ticagrelor is used in the treatment of acute coronary syndromes (ACS).

ZD 2486 is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist. It inhibits platelet aggregation by blocking the binding of fibrinogen to the GP IIb/IIIa receptors on platelets. ZD 2486 is applicable in research concerning diseases linked to undesirable platelet aggregation, such as acute coronary syndromes, unstable angina, acute myocardial infarction, and complications from cardiovascular interventions.